A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer - PACIFIC-9

Study identifier:D9078C00001

ClinicalTrials.gov identifier:NCT05221840

EudraCT identifier:2021-004346-37

CTIS identifier:N/A

Recruiting

Official Title

A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy

Medical condition

Non-small Cell Lung Cancer

Phase

Phase 3

Healthy volunteers

No

Study drug

Durvalumab, Oleclumab, Monalizumab

Sex

All

Estimated Enrollment

999

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 07 Feb 2022
Estimated Primary Completion Date: 29 May 2026
Estimated Study Completion Date: 31 May 2030

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria